布洛芬-d3 | 121662-14-4

• 物质功能分类: 化学试剂 - 氘代试剂
• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 中文名称: 布洛芬-d3
• 中文别名: 氘代布洛芬
• 英文名称: <2-2H3> ibuprofen
• 英文别名: ibuprofen-d3；rac Ibuprofen-d3；3,3,3-trideuterio-2-[4-(2-methylpropyl)phenyl]propanoic acid
• CAS: 121662-14-4
• 化学式: C₁₃H₁₈O₂
• 分子量: 209.261
• InChiKey: HEFNNWSXXWATRW-HPRDVNIFSA-N

物化性质

• 熔点：
  69-71°C
• 闪点：
  9℃
• 溶解度：
  可溶于乙腈（少量）、氯仿（少量）、乙醇（少量，超声处理）、

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xn,N
• 安全说明：
  S61
• 危险类别码：
  R22,R51/53
• WGK Germany：
  2
• 危险标志：
  GHS02,GHS06,GHS08
• 危险品运输编号：
  UN3077 9/PG 3
• 危险性描述：
  H225,H301 + H311 + H331,H370
• 危险性防范说明：
  P210,P280,P302 + P352 + P312,P304 + P340 + P312,P370 + P378,P403 + P235

SDS

---

Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
Product identifiers
Product name : Ibuprofen-d3
: Fluka
CAS-No. : 121662-14-4

---

Section 2. HAZARDS IDENTIFICATION
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008 [EU-GHS/CLP]
Acute toxicity, Oral (Category 4)
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Harmful if swallowed. Toxic to aquatic organisms, may cause long-term adverse effects in the aquatic
environment.
Label elements
Labelling according Regulation (EC) No 1272/2008 [CLP]
Pictogram
Signal word Warning
Hazard statement(s)
Harmful if swallowed.
Precautionary statement(s) none
Supplemental Hazard none
Statements
According to European Directive 67/548/EEC as amended.
Hazard symbol(s)
R-phrase(s)
R22 Harmful if swallowed.
R51/53 Toxic to aquatic organisms, may cause long-term adverse effects in the
aquatic environment.
S-phrase(s)
S61 Avoid release to the environment. Refer to special instructions/ Safety
data sheets.
Other hazards - none

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substances
: α-Methyl-d3-4-(isobutyl)phenylacetic acid
Synonyms
Formula : C13D3H15O2
Molecular Weight : 209,30 g/mol
Component Concentration
Ibuprofen-d
CAS-No. 121662-14-4 -

---

Section 4. FIRST AID MEASURES
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
Indication of any immediate medical attention and special treatment needed
no data available

---

Section 5. FIREFIGHTING MEASURES
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapors, mist or gas. Ensure
adequate ventilation. Avoid breathing dust.
Environmental precautions
Prevent further leakage or spillage if safe to do so. Do not let product enter drains. Discharge into the
environment must be avoided.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.Normal measures for preventive fire
protection.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Store under inert gas.
Specific end uses
no data available

---

Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested
and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Immersion protection
Material: Nitrile rubber
Minimum layer thickness: 0,11 mm
Break through time: > 480 min
Splash protection
Material: Nitrile rubber
Minimum layer thickness: 0,11 mm
Break through time: > 30 min
test method: EN374
If used in solution, or mixed with other substances, and under conditions which differ from EN 374,
contact the supplier of the CE approved gloves. This recommendation is advisory only and must
be evaluated by an Industrial Hygienist familiar with the specific situation of anticipated use by our
customers. It should not be construed as offering an approval for any specific use scenario.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher
level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges.
Use respirators and components tested and approved under appropriate government standards
such as NIOSH (US) or CEN (EU).

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing 75 - 77,5 °C
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evaporation rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility insoluble
o) Partition coefficient: n- log Pow: -0,23 - 3,3 at 25 °C
octanol/water
p) Autoignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

Section 10. STABILITY AND REACTIVITY
Reactivity
no data available
Chemical stability
no data available
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
no data available
Hazardous decomposition products
Other decomposition products - no data available

---

Section 11. TOXICOLOGICAL INFORMATION
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation
May be harmful if inhaled. May cause respiratory tract irritation.
Ingestion Harmful if swallowed.
Skin May be harmful if absorbed through skin. May cause skin irritation.
Eyes May cause eye irritation.
Additional Information
RTECS: Not available

---

Section 12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
no data available
Other adverse effects
Toxic to aquatic life.

---

Section 13. DISPOSAL CONSIDERATIONS
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed
professional waste disposal service to dispose of this material. Dissolve or mix the material with a
combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

Section 14. TRANSPORT INFORMATION
UN number
ADR/RID: 3077 IMDG: 3077 IATA: 3077
UN proper shipping name
ADR/RID: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Ibuprofen-d )
IMDG: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Ibuprofen-d )
IATA: Environmentally hazardous substance, solid, n.o.s. (Ibuprofen-d )
Transport hazard class(es)
ADR/RID: 9 IMDG: 9 IATA: 9
Packaging group
ADR/RID: III IMDG: III IATA: III
Environmental hazards
ADR/RID: yes IMDG Marine pollutant: yes IATA: yes
Special precautions for user
Further information
EHS-Mark required (ADR 2.2.9.1.10, IMDG code 2.10.3) for single packagings and combination
packagings containing inner packagings with Dangerous Goods > 5L for liquids or > 5kg for solids.

---

Section 15. REGULATORY INFORMATION
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
no data available
Chemical Safety Assessment
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

生物活性方面，Ibuprofen D3 是一种氘代的 Ibuprofen。Ibuprofen 能够抑制 COX-1 和 COX-2，其 IC50 值分别为 13 μM 和 370 μM。

反应信息

• 作为产物：
  描述：

  (4-异丁基苯基)乙腈 在 deuterated dimethylamine borane complex 、 potassium tert-butylate 、 水 、 sodium hydroxide 作用下， 以 乙醇 为溶剂， 反应 17.0h， 生成 布洛芬-d3
  参考文献：
  名称：

  一种α-氘代甲基芳基丙酸类非甾体抗炎药的合成方法

  摘要：

  本发明公开了一种α‑氘代甲基芳基丙酸类非甾体抗炎药的合成方法，特征是以芳基乙腈类化合物作为底物，使用氘代胺硼烷络合物、氘代N,N‑二甲基甲酰胺分别或共同作为氘代试剂，在碱性条件下，可分别得到α‑单氘代、双氘代或三氘代甲基芳基丙腈类化合物，再在强碱性条件下水解，即得到相应的氘代甲基芳基丙酸类非甾体抗炎药。本发明首次实现了在非甾体抗炎药芳基丙酸类化合物的甲基上，选择性将氢原子置换为氘原子，并且引入的氘原子数目可以精确控制。氘原子在这些药物分子中的引入，可直接影响药物的吸收、分布、代谢和排泄等属性，从而提高药物的疗效、安全性和耐受性。

  公开号：

  CN108003004A

文献信息

• A comparative study on the photo-induced arylation of β-dicarbonyl compounds by arylazosulfides and its use in the synthesis of methyl labeled 2-arylpropionic acids
  作者：Mercè Tona、Francisco Sánchez-Baeza、Angel Messeguer

  DOI：10.1016/s0040-4020(01)85294-7

  日期：1994.1

  corresponding arylation adducts in satisfactory yields. Concerning the β-dicarbonyl derivatives, condensation of acetylacetone in the case of 1 and of dimethyl malonate in that of 11 gave the best results. However, the further methylation of the aryl β-dicarbonyl adduct was clearly advantageous for the case of the 2-arylmalonate derivatives. The use of this synthetic strategy for the convenient preparation of

  提出了一种通过光诱导分解芳基偶氮硫化物使β-二羰基衍生物（乙酰丙酮，乙酰乙酸甲酯和丙二酸二甲酯）芳基化的比较研究。所使用的芳基偶氮硫化物包含与酮洛芬或布洛芬有关的芳基部分，并且该反应按照Dell'Erba等人的报告的方法进行。（四面体，1991，47，333）。从所分析的芳基偶氮硫化物，仅那些带有与苯环连接的羰基的那些，即1和11，以令人满意的产率提供了相应的芳基化加合物。关于β-二羰基衍生物，在1的情况下乙酰丙酮的缩合。丙二酸二甲酯中11的结果最好。然而，对于2-芳基丙二酸酯衍生物的情况，芳基β-二羰基加合物的进一步甲基化显然是有利的。使用该合成策略方便地制备在C-2处的甲基标记的酮洛芬（23％的总产率，3-硝基二苯甲酮7步）和布洛芬（34％的总产率，4异丁酰苯8步）异位异构体也有报道。
• CHEN, CHING-SHIH;COPELAND, DEBRA;HARRIMAN, SHAWN;LIU, YEUK-CHUEN, J. LABELL. COMPOUNDS AND RADIOPHARM., 28,(1990) N, C. 1017-1024
  作者：CHEN, CHING-SHIH、COPELAND, DEBRA、HARRIMAN, SHAWN、LIU, YEUK-CHUEN

  DOI：——

  日期：——
• Tona Merce, Sanchez-Baeza Francisco, Messeguer Angel, Tetrahedron, 50 (1994) N 27, S 8117-8126
  作者：Tona Merce, Sanchez-Baeza Francisco, Messeguer Angel

  DOI：——

  日期：——
• 一种α-氘代甲基芳基丙酸类非甾体抗炎药的合成方法
  申请人：中国科学技术大学

  公开号：CN108003004A

  公开（公告）日：2018-05-08

  本发明公开了一种α‑氘代甲基芳基丙酸类非甾体抗炎药的合成方法，特征是以芳基乙腈类化合物作为底物，使用氘代胺硼烷络合物、氘代N,N‑二甲基甲酰胺分别或共同作为氘代试剂，在碱性条件下，可分别得到α‑单氘代、双氘代或三氘代甲基芳基丙腈类化合物，再在强碱性条件下水解，即得到相应的氘代甲基芳基丙酸类非甾体抗炎药。本发明首次实现了在非甾体抗炎药芳基丙酸类化合物的甲基上，选择性将氢原子置换为氘原子，并且引入的氘原子数目可以精确控制。氘原子在这些药物分子中的引入，可直接影响药物的吸收、分布、代谢和排泄等属性，从而提高药物的疗效、安全性和耐受性。